E-Mail Alert

Add your e-mail address to receive forthcoming issues of this journal:

Journal Browser

Journal Browser

Special Issue "Anti-Cancer Drug: Discovery, Development and Combination"

A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".

Deadline for manuscript submissions: 31 March 2020

Special Issue Editor

Guest Editor
Assoc. Prof. Yasuyoshi Miyata

Nagasaki University Graduate School of Biomedical Sciences, Department of Urology, Nagasaki, Japan
Website | E-Mail
Interests: anti-cancer drug, promising anti-cancer target, translational research, clinical trial, conservative therapy, peri-operative therapy, quality of life, natural products

Special Issue Information

Dear Colleagues,

Cancer is recognized as a multifactorial disease and its progression is regulated by extremely complex mechanisms. Indeed, numerous factors, such as DNA methylation, miRNA, growth factors, angiogenesis, and the immune system, are closely associated with carcinogenesis, invasion, metastasis, and prognosis. In addition, a variety of molecules, cancer stem cells, and long non-coding RNAs play important roles in the resistance to cancer therapies. Furthermore, the contribution of such carcinogenic factors to malignant behavior is dependent on the type of cancer and the stage of the disease.

Armed with this knowledge, researchers have discovered many promising candidates for cancer therapy, and some are now being tested in clinical trials. Various new therapeutic targets, including chemical compounds and natural products, have been identified from basic and translational studies.

The aim of this Special Issue is to collect research papers, reviews, and communications focused on the discovery and development of anti-cancer drugs, as well as potential therapeutic targets, for various types of cancers. Moreover, clinical and translational studies on anti-cancer drugs used to improve the efficacy of conservative therapies, to decrease the number of residual cancer cells after operation, and to maintain the quality of life in patients with cancer, are invited.

Assoc. Prof. Yasuyoshi Miyata
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • Anti-Cancer therapy;
  • Promising target;
  • Conservative therapy;
  • Peri-operative therapy;
  • Natural product.

Published Papers

This special issue is now open for submission.
Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top